TORONTO, May 30, 2013 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") announces that the nominees listed in the management information circular for the annual and special meeting (the "Meeting") of shareholders held on Tuesday, May 28, 2013 were elected as directors of GeneNews.
Detailed results of the vote for the election of directors are set out below.
Nominees | Votes FOR | % FOR | Votes WITHHELD | % WITHHELD |
Heiner Dreismann | 13,382,089 | 99.48 | 69,432 | 0.52 |
Gailina Liew | 13,382,089 | 99.48 | 69,432 | 0.52 |
Rory Riggs | 13,382,089 | 99.48 | 69,432 | 0.52 |
Garth MacRae | 13,382,089 | 99.48 | 69,432 | 0.52 |
David Sable | 13,382,089 | 99.48 | 69,432 | 0.52 |
Harry Glorikian | 13,382,089 | 99.48 | 69,432 | 0.52 |
James Howard-Tripp | 13,382,089 | 99.48 | 69,432 | 0.52 |
About GeneNews
GeneNews is a molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic tests through the application of functional genomics to enable early diagnosis and personalized health management. The Company has developed a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews has applied the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' lead product, ColonSentry®, is the world's first blood test to assess an individual's current risk for colorectal cancer. For more information on GeneNews and ColonSentry®, go to www.GeneNews.com or www.ColonSentry.com.
Forward-Looking Statements
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.